drugset / Trial / NCT02024646

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

NCT02024646

Phase 3 Completed 484 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.

Timeline

Start
2014-03
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Brodalumab Monoclonal antibody 140 mg Subcutaneous
Subject Brodalumab Monoclonal antibody 210 mg Subcutaneous

Indications